Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

MRI Characteristics of LGI1- and CASPR2-antibody Encephalitis: Independent Discovery and Validation Cohorts
Autoimmune Neurology
C15 - Suspecting Autoimmune Encephalitis: And Now What? (2:41 PM-2:48 PM)
P3 - Poster Session 3 (12:00 PM-1:00 PM)
002

Rapid and accurate diagnosis of AE encourages prompt immunotherapy initiation, towards improved patient outcomes. However, clinical features alone may not sufficiently narrow the differential diagnosis. Further, awaiting autoantibody results can delay immunotherapy administration.

To identify simple MRI characteristics which accurately distinguish two common forms of autoimmune encephalitis (AE); LGI1- and CASPR2-antibody encephalitis (LGI1/CASPR2-Ab-E), from two major differential diagnoses, viral encephalitis (VE) and Creutzfeldt-Jakob disease (CJD).

Retrospective, cross-sectional, blinded analysis of first available brain MRIs from 192 patients across two tertiary referral centres with LGI1/CASPR2-Ab-E, VE or CJD evaluated for predetermined MRI features by two neuroradiologists (discovery cohort; n=87) and validated in an independent cohort by three neurologists (n=105). Groups were statistically compared with contingency tables.

MRIs from 192 participants were reviewed (n = 71 female, 37%; median age = 66). By comparison to VE and CJD, in LGI1/CASPR2-Ab-E T2/FLAIR-hyperintensities were less likely to extend outside the temporal lobe (7% vs 94% in VE; P<0.001 and 75% in CJD; P<0.01), less frequently exhibited swelling (22% of LGI1/CASPR2-Ab-E vs 59% of VE; P<0.001), and showed no diffusion restriction (0%, vs 73% in VE and 80% in CJD; both P<0.001) and rare contrast-enhancement (5% vs 41% in VE, P=0.013). These findings were validated in an independent cohort and generated an area under the curve of 0.97, sensitivity of 90% and specificity 95% amongst cases with T2/FLAIRhyperintensity in the hippocampus and/or amygdala.

T2/FLAIR-hyperintensities confined to the temporal lobes, without diffusion restriction or contrast-enhancement, robustly distinguish LGI1/CASPR2-Ab-E from key differentials. These observations should assist clinical decision making towards expediting immunotherapy. Their generalisability to other forms of AE/VE should be examined in future studies.

Authors/Disclosures
Mark J. Kelly, MBBS (Royal College of Surgeons in Ireland)
PRESENTER
The institution of Dr. Kelly has received research support from The Health Research Board / Wellcome Trust.
Eleanor Grant No disclosure on file
Andrew Murchison No disclosure on file
Sophie Binks The institution of Ms. Binks has received research support from Wellcome Trust. The institution of Ms. Binks has received research support from PetSavers. The institution of Ms. Binks has received research support from PetPlan. The institution of Ms. Binks has received research support from NIHR. Ms. Binks has received intellectual property interests from a discovery or technology relating to health care. Ms. Binks has received personal compensation in the range of $0-$499 for serving as a Speaker with ECTRIMS. Ms. Binks has received personal compensation in the range of $0-$499 for serving as a Speaker with Vetmeduni Wien. Ms. Binks has received personal compensation in the range of $0-$499 for serving as a Speaker with ANA. Ms. Binks has a non-compensated relationship as a Speaker with Encephalitis Society UK that is relevant to AAN interests or activities.
Sudarshini Ramanathan, MBBS, PhD, FRACP (University of Sydney) Dr. Ramanathan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for UCB. Dr. Ramanathan has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Biogen, Alexion, Novartis. Dr. Ramanathan has received research support from NHMRC, RACP, University of Sydney.
Sophia Michael, PhD, MBChB; DPhil (Oxon) Dr. Michael has nothing to disclose.
Adam Handel No disclosure on file
Lahiru Handunnetthi, MBBS The institution of Dr. Handunnetthi has received research support from Janssen Pharmaceuticals.
Christopher E. Uy, MD (Vancouver Coastal Health) Dr. Uy has nothing to disclose.
Fintan Sheerin No disclosure on file
Eoin P. Flanagan, MBBCh, FAAN (Mayo Clinic) The institution of Dr. Flanagan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. Dr. Flanagan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Genentech. Dr. Flanagan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Horizon Therapeutics. The institution of Dr. Flanagan has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Dr. Flanagan has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Pharmacy times. The institution of Dr. Flanagan has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for UCB. The institution of Dr. Flanagan has received research support from Viela Bio. The institution of Dr. Flanagan has received research support from UCB. The institution of Dr. Flanagan has received research support from Roche. Dr. Flanagan has received publishing royalties from a publication relating to health care. Dr. Flanagan has a non-compensated relationship as a Member of medical Advisory Board with The MOG Project that is relevant to AAN interests or activities. Dr. Flanagan has a non-compensated relationship as a Editorial board member with Journal of The Neurologic Sciences that is relevant to AAN interests or activities. Dr. Flanagan has a non-compensated relationship as a Editorial board member with Neuroimmunology Reports that is relevant to AAN interests or activities. Dr. Flanagan has a non-compensated relationship as a Editorial Board Member with Neurology, Neuroimmunology Neuroinflammation (N2) Journal that is relevant to AAN interests or activities.
Gregory S. Day, MD, MSc, FAAN (Mayo Clinic) Dr. Day has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Parabon Nanolabs. The institution of Dr. Day has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Eli Lilly. Dr. Day has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Arialys Therapeutics. Dr. Day has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Ionis. Dr. Day has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for DynaMed (EBSCO Health). Dr. Day has stock in ANI Pharmaceuticals. The institution of Dr. Day has received research support from National Institutes of Health / NIA. The institution of Dr. Day has received research support from Chan Zuckerberg Initiative. The institution of Dr. Day has received research support from Alzheimer's Association. The institution of Dr. Day has received research support from National Institutes of Health / NINDS. The institution of Dr. Day has received research support from Horizon Therapeutics. The institution of Dr. Day has received research support from AVID Radiopharmaceuticals. Dr. Day has received personal compensation in the range of $500-$4,999 for serving as a Presenter at Annual Meeting (CME) with American Academy of Neurology. Dr. Day has received personal compensation in the range of $500-$4,999 for serving as a Content Development (CME) with PeerView, Inc. Dr. Day has received personal compensation in the range of $5,000-$9,999 for serving as a Content Development (CME) with Continuing Education, Inc. Dr. Day has a non-compensated relationship as a Clinical Director with AntiNMDA Receptor Encephalitis Foundation that is relevant to AAN interests or activities.
Alfonso S. Lopez, MD (Mayo Clinic) Dr. Lopez has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Horizon. Dr. Lopez has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Genentech .
Divyanshu Dubey, MD, FAAN (Mayo Clinic) The institution of Dr. Dubey has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Argenx. The institution of Dr. Dubey has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Arialys. The institution of Dr. Dubey has received personal compensation in the range of $500-$4,999 for serving as a Consultant for UCB . Dr. Dubey has received research support from Department of Defense . Dr. Dubey has received research support from Department of Defense . Dr. Dubey has received research support from UCB. Dr. Dubey has received research support from David J. Tomassoni ALS Research Grant Program . Dr. Dubey has received intellectual property interests from a discovery or technology relating to health care. Dr. Dubey has received intellectual property interests from a discovery or technology relating to health care. Dr. Dubey has received intellectual property interests from a discovery or technology relating to health care. Dr. Dubey has received intellectual property interests from a discovery or technology relating to health care.
John N. Soltys, MD (Mayo Clinic) Dr. Soltys has nothing to disclose.
Sarosh R. Irani, MD, PhD, FRCP, FEAN (Mayo Clinic) Dr. Irani has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for UCB, Cerebral therapeutics, Roche and Janssen. Dr. Irani has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for UCB. Dr. Irani has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Dr. Irani has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Brain. Dr. Irani has received personal compensation in the range of $100,000-$499,999 for serving as an Expert Witness for LLPs. Dr. Irani has received intellectual property interests from a discovery or technology relating to health care. Dr. Irani has received intellectual property interests from a discovery or technology relating to health care. Dr. Irani has received intellectual property interests from a discovery or technology relating to health care.